Abstract
Most current approaches to estimating HIV incidence and the size of the undiagnosed population do not account for pre-migration infections, although these represent a substantial fraction of new diagnoses in some European countries. We propose a new approach to estimating these indicators that explicitly accounts for migration. First, we use an existing Bayesian model to estimate delays between infection and diagnosis for each newly diagnosed individual, and classify those born abroad into pre- or post-migration infections. Second, for native-born individuals and those with post-migration infections, we use a repurposed regression model to describe the global distribution of delays between infection and diagnosis, and estimate HIV incidence. For people with pre-migration infections, the same model is used to describe the delays between migration and diagnosis, and subsequently estimate the number of arriving migrants with undiagnosed HIV. Finally, these estimates are combined to estimate the number of people in the country with undiagnosed HIV. When applied to simulated data inspired by the French HIV surveillance system, the new model appropriately corrects for pre-migration HIV infections and produces estimates of HIV incidence, arrival of people with undiagnosed HIV, and the size of the undiagnosed population that are similar to the true simulated values.
Competing Interest Statement
NP has received grants unrelated to this study and paid to his institution from Gilead Sciences Hellas and European Centre for Disease Prevention and Control. The remaining authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This article describes a simulated dataset that was constructed to have similar characteristics to data from the French HIV surveillance system. Pseudonymous notification of all new HIV diagnoses has been mandatory since 2003 according to French law. The French data protection authority approved the variables collected for this surveillance.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The simulated data presented here and programs needed to run the model are included as supplementary material.
